Search
Selected Filter
Displaying 11–20 of 244 research results
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Known as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Optogenetics: Hope for Vision Restoration for Advanced Retinal Diseases
Early, encouraging results from two human studies — trials launched by Bionic Sight and GenSight — are putting optogenetic therapies in the spotlight for patients with advanced vision loss from retinal conditions.
-
Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
While the trial is for people with RP, the company hopes it will also benefit people with other retinal degenerative diseases
-
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Additional results from the trial will be reported at a future scientific meeting
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
The gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
More details from the clinical trial will be reported at a later date
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
The company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Gene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
